IFEX POWDER FOR SOLUTION

国家: 加拿大

语言: 英文

来源: Health Canada

有效成分:

IFOSFAMIDE

可用日期:

BAXTER CORPORATION

ATC代码:

L01AA06

INN（国际名称）:

IFOSFAMIDE

剂量:

3G

药物剂型:

POWDER FOR SOLUTION

组成:

IFOSFAMIDE 3G

给药途径:

INTRAVENOUS

每包单位数:

60ML

处方类型:

Prescription

治疗领域:

ANTINEOPLASTIC AGENTS

產品總結:

Active ingredient group (AIG) number: 0120706001; AHFS:

授权状态:

APPROVED

授权日期:

2002-02-04

产品特点

_ _
IFEX Product Monograph
Page 1 of 37
PRODUCT MONOGRAPH
PR
IFEX
(Ifosfamide for Injection)
Powder for Solution, 1 g/vial and 3 g/vial
Antineoplastic Agent
Baxter Corporation
Mississauga, Ontario
Canada L5N 0C2
Date of Revision:
June 27, 2018
Submission Control No.: 213560
Baxter and Ifex are trademarks of Baxter International Inc., its
subsidiaries or affiliates.
_ _
IFEX Product Monograph
Page 2 of 37
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
..................................................................................................13
DRUG INTERACTIONS
..................................................................................................20
DOSAGE AND ADMINISTRATION
..............................................................................25
OVERDOSAGE
................................................................................................................27
ACTION AND CLINICAL PHARMACOLOGY
............................................................27
STORAGE AND STABILITY
..........................................................................................28
SPECIAL HANDLING INSTRUCTIONS
.......................................................................28
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................29
PART II: SCIENTIFIC INFORMATION
...............................................................................30
PHARMACEUTICAL INFORMATION
.....................................................................